loader
Please Wait
Applying Filters...

Suanfarma Suanfarma

X

Technical details about Tafenoquine Succinate, learn more about the structure, uses, toxicity, action, side effects and more

Client Email Product
Menu
2D Structure
1. Also known as: 106635-81-8, Wr-238605, Tafenoquine succinate [usan], Tafenoquine (succinate), Dl5j0b8vss, 106635-81-8 (succinate)
Molecular Formula
C28H34F3N3O7
Molecular Weight
581.6  g/mol
InChI Key
CQBKFGJRAOXYIP-UHFFFAOYSA-N
FDA UNII
DL5J0B8VSS

Tafenoquine Succinate is the succinate salt form of tafenoquine, an orally bioavailable 8-aminoquinoline derivative, with antimalarial activity. Although the mechanism is not completely understood, upon administration, tafenoquine inhibits the parasitic enzyme heme polymerase in the blood stages of the parasites. This inhibits the conversion of the toxic heme into non-toxic hemazoin, thereby resulting in the accumulation of toxic heme within the parasite. Tafenoquine is active against all the stages of Plasmodium species and is also active against the pre-erythrocytic liver stages of the parasites. This prevents the development of the erythrocytic forms of the parasite which are responsible for relapses in P. vivax malaria.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
butanedioic acid;4-N-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl]pentane-1,4-diamine
2.1.2 InChI
InChI=1S/C24H28F3N3O3.C4H6O4/c1-14-11-20(32-4)30-22-18(29-15(2)7-6-10-28)13-19(31-3)23(21(14)22)33-17-9-5-8-16(12-17)24(25,26)27;5-3(6)1-2-4(7)8/h5,8-9,11-13,15,29H,6-7,10,28H2,1-4H3;1-2H2,(H,5,6)(H,7,8)
2.1.3 InChI Key
CQBKFGJRAOXYIP-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=CC(=NC2=C1C(=C(C=C2NC(C)CCCN)OC)OC3=CC=CC(=C3)C(F)(F)F)OC.C(CC(=O)O)C(=O)O
2.2 Other Identifiers
2.2.1 UNII
DL5J0B8VSS
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (r)-tafenoquine Succinate

2. Arakoda

3. Butanedioic Acid, Compd. With N4-(2,6-dimethoxy-4-methyl-5-(3-(trifluoromethyl)phenoxy)-8-quinolinyl)-1,4-pentanediamine (1:1)

4. Butanedioic Acid, Compd. With N4-(2,6-dimethoxy-4-methyl-5-(3-(trifluoromethyl)phenoxy)-8-quinolinyl)-1,4-pentanediamine (1:1), (r)-

5. Krintafel

6. N(4)-(2,6-dimethoxy-4-methyl-5-((3-trifluoromethyl)phenoxy)-8-quinolinyl)-1,4-pentanediamine

7. Sb-252263-ax

8. Sb-252263ax

9. Sb252263-ax

10. Sb252263ax

11. Tafenoquine

12. Tafenoquine Maleate

13. Tafenoquine Succinate, (r)-

14. Wr 238605

15. Wr-238605

16. Wr238605

2.3.2 Depositor-Supplied Synonyms

1. 106635-81-8

2. Wr-238605

3. Tafenoquine Succinate [usan]

4. Tafenoquine (succinate)

5. Dl5j0b8vss

6. 106635-81-8 (succinate)

7. Arakoda

8. Krintafel

9. Sb-252263-ax

10. Wr238605 Succinate

11. Butanedioic Acid, Compd. With N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolinyl]-1,4-pentanediamine (1:1)

12. Tafenoquine Succinate (usan)

13. N4-(2,6-dimethoxy-4-methyl-5-(3-(trifluoromethyl)phenoxy)quinolin-8-yl)pentane-1,4-diamine Succinate

14. N4-(2,6-dimethoxy-4-methyl-5-(3-(trifluoromethyl)phenoxy)quinolin-8-yl)pentane-1,4-diamine Succinate(1:1)

15. Unii-dl5j0b8vss

16. Sb-252263

17. Krintafel (tn)

18. Butanedioic Acid, Compd. With N4-(2,6-dimethoxy-4-methyl-5-(3-(trifluoromethyl)phenoxy)-8-quinolinyl)-1,4-pentanediamine (1:1)

19. Arakoda (tn)

20. Wr 238605 Succinate

21. Butanedioic Acid, Compd. With N(sup 4)-(2,6-dimethoxy-4-methyl-5-(3-(trifluoromethyl)phenoxy)-8-quinolinyl)-1,4-pentanediamine (1:1)

22. Mls006010680

23. Wr 238605 (succinate)

24. Schembl1004186

25. Chembl2364635

26. Dtxsid10910065

27. Tafenoquine Succinate [mi]

28. Akos037648507

29. Tafenoquine Succinate [who-dd]

30. Hy-111529a

31. Tafenoquine Succinate, >=95% (hplc)

32. Bs-14295

33. Butanedioic Acid;4-n-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl]pentane-1,4-diamine

34. Smr004701662

35. Tafenoquine Succinate [orange Book]

36. Cs-0083862

37. D10670

38. D80913

39. A904698

40. Q27276464

41. (4rs)-n4-(2,6-dimethoxy-4-methyl-5-(3-(trifluoromethyl)phenoxy)quinolin-8-yl)pentane-1,4-diamine Butanedioate

42. 8-[(4-amino-1-methylbutyl)amino]-2,6-dimethoxy-4-methyl-5-(3-trifluoromethylphenoxy)quinoline Succinate

43. 8-[(4-amino-1-methylbutyl)amino]-2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinoline Succinate

44. N4-(2,6-dimethoxy-4-methyl-5-(3-(trifluoromethyl)phenoxy)quinolin-8-yl)pentane-1,4-diaminesuccinate(1:1)

2.4 Create Date
2005-08-08
3 Chemical and Physical Properties
Molecular Weight 581.6 g/mol
Molecular Formula C28H34F3N3O7
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count13
Rotatable Bond Count12
Exact Mass581.23488492 g/mol
Monoisotopic Mass581.23488492 g/mol
Topological Polar Surface Area153 Ų
Heavy Atom Count41
Formal Charge0
Complexity690
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Antimalarials

Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)


Post Enquiry
POST ENQUIRY